Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Shorting stocks: High fliers -- Ignore unavailable to you. Want to Upgrade?

To: drakes353 who wrote (526)	8/29/1998 4:46:00 PM
From: Harpo	Respond to of 709

<< So, anyone tried borrowing this thing yet?>> Hi Drakes, Not yet. It's gone up a little bit the last few days on pretty good volume in spite of everything. Maybe it's because of the recent press release. I was thinking about taking another look at it when some of the excitement starts wearing off and the volume starts to die off a little, what do you think? regards, Ben

To: drakes353 who wrote (526)	8/31/1998 8:47:00 AM
From: Q.	Read Replies (1) \| Respond to of 709

Drakes, re. HEB, I think it's an interesting idea to identify small US stocks that have recently started trading in Germany. This seems to cause the share price to increase, at least in the two cases I've looked at (TRBD and HEB). I was able to borrow HEB shares. I should backtrack on one thing I suggested about HEB in my previous post. While it is true that the German firm 'Value Management & Research' did a report on HEB, and arranged for them to get listed in Germany, after talking to one of their analysts, I no longer think VMR is merely a 'tout' that is paid solely by the listed companies. There are other reasons I think HEB is a good short, though, and these are: * Most importantly, shares from the 1997 private placement go out of lockout very soon. * The market cap is about 40 X the annual run rate for R&D, which is way too high for a development-stage biotech. * HEB was brought public in 1995 by Stratton Oakmont, which doesn't have the best reputation, and